Pain Management · NSAIDRegulatory Approvalcommercialnear-term

FDA Grants AP Status for Piroxicam ANDA210347 by Strides Pharma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Strides Pharma10 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/1/2026, 12:30:52 PM

Assessment confidence: 62% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Strides Pharma's ANDA for Piroxicam introduces a generic competitor into the pain management market. This could lead to significant pricing pressures and market share shifts for existing branded products, necessitating strategic adjustments from current market players. Regulatory context from FDA (FDA AP — PIROXICAM (SUPPL)) supports the near-term read. Assessment grounded in 5 ranked evidence items (2 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this generic entry on existing pain management products and consider pricing strategies. The strongest clinical anchor is Evaluation of the Japet.W+ Medical Device for Low Back Pain Management (ClinicalTrials.gov), sub-indication match (pain). In pain, 2 regulatory and 1 competitive items passed relevance filtering for Strides Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc (Humanexa Signals) — sub-indication match (pain). This approval allows Strides Pharma to enter the market with a generic version of Piroxicam, potentially impacting pricing and market share of existing branded products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PIROXICAM (SUPPL) (FDA). Entity match (strides pharma); Regulatory pathway relevance (nda). While the approval indicates compliance with FDA standards, it also highlights the ongoing regulatory pathway for generics, which could influence future submissions and competitive strategies.

Key Risks

Elevated medium regulatory exposure for Strides Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of a generic version of Piroxicam is likely to disrupt pricing dynamics, potentially leading to decreased revenues for existing branded products in the pain management category.
Portfolio teams should assess the impact of this generic entry on existing pain management products and consider pricing strategies.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and pricing strategies of Strides Pharma for Piroxicam.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PIROXICAM (SUPPL)
FDAmedium relevance
Entity match (strides pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PIROXICAM (SUPPL)
FDAmedium relevance
Entity match (strides pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
Class 4 Medicines Defect Notification: Brancaster Pharma Limited, Benzylpenicillin benzathine 1.2 Million I.U. and 2.4 Million I.U. powder for suspension for injection, EL(26)A/30
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Efficacy of Dexmedetomidine VS Magnesium Sulphate With Bupivacaine in Erector Spinae Block for Thoracotomy Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Suction Mini-PCNL Versus Standard PCNL for the Management of 2-4cm Kidney Stones
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effect of Foot Massage on Pain and Analgesic Consumption in Total Knee Prosthesis
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study of the Impact of Virtual Reality Medical Device (HypnoVR® Headset) on Anxiety and Pain in Interventional Radiology.
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Phase Ⅱ Study to Evaluate the Efficacy and Safety of YZJ-4729 in Patients With Moderate to Severe Acute Pain After Abdominal Surgery
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc
Humanexa Signalsmedium relevance
Sub-indication match (pain)
FDA Grants Priority Review for TRYNGOLZA Autoinjector Submission
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Strides Pharma
Piroxicam

Commercial impact

high

The entry of a generic version of Piroxicam is likely to disrupt pricing dynamics, potentially leading to decreased revenues for existing branded products in the pain management category.

Regulatory impact

medium

While the approval indicates compliance with FDA standards, it also highlights the ongoing regulatory pathway for generics, which could influence future submissions and competitive strategies.

What to watch

Monitor market entry timelines and pricing strategies of Strides Pharma for Piroxicam.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.